Sector consensus Revolution Medicines, Inc.
Equities
RVMD
US76155X1000
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.74 USD | -0.77% |
|
-0.22% | +21.46% |
| 01-29 | Revolution Medicines Says First Patient Dosed in Solid Tumor Trial | MT |
| 01-29 | Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | US$119.37 | +22.44% | 19 | ||||||
| CHF 673.39 | +30.2% | 23 | ||||||
| US$405.42 | +14.55% | 24 | ||||||
| ₩249,772.73 | +13.53% | 22 | ||||||
| US$247.35 | +31.93% | 20 | ||||||
| US$545.75 | +0.68% | 12 | ||||||
| €70.26 | +3.32% | 15 | ||||||
| US$91.13 | +5.35% | 22 | ||||||
| US$233.91 | +24.15% | 16 | ||||||
| US$206.38 | +37.04% | 16 | ||||||
| US$54.46 | +6.89% | 14 | ||||||
| US$75.25 | +12.68% | 12 | ||||||
| US$87.92 | +60.11% | 12 | ||||||
| US$215.73 | +14.02% | 15 | ||||||
| Average | 18,057.07 | +19.78% | 17 | ||||||
| Weighted average by Cap. | 29,821.51 | +20.41% | 19 |
- Stock Market
- Equities
- RVMD Stock
- Sector Revolution Medicines, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition